RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
HIV-infected individuals with CD4 count > 100 cells/L with cryptococcal meningitis presented more frequently with altered mental status despite having a 10-fold lower fungal burden. The survival by extremes of low and high CD4 are consistent with the damage-response framework theory.Cryptococcal meningitis can occur in persons with less-apparent immunosuppression. We evaluated clinical characteristics and outcomes of persons with HIV-related Cryptococcus presenting with higher CD4 counts.We enrolled 736 participants from 2 prospective cohorts in Uganda and South Africa from November 2010 to May 2017. We compared participants with CD4 < 50, 5099, or 100 cells/L by clinical characteristics, cerebrospinal fluid (CSF) parameters, and 18-week survival.Among first episode of cryptococcosis, 9% presented with CD4 100 cells/L. Participants with CD4 100 cells/L presented more often with altered mental status (52% vs 39%; P = .03) despite a 10-fold lower initial median CSF fungal burden of 7850 (interquartile range [IQR] 86065500) versus 79000 (IQR 7400380000) colony forming units/mL (P < .001). Participants with CD4 100 cells/L had higher median CSF levels of interferon-gamma, interleukin (IL)-6, IL-8, and IL-13, and lower monocyte chemokine, CCL2 (P < .01 for each). Death within 18 weeks occurred in 47% with CD4 < 50, 35% with CD4 5099, and 40% with CD4 100 cells/L (P = .04).HIV-infected individuals developing cryptococcal meningitis with CD4 100 cells/L presented more frequently with altered mental status despite having 10-fold lower fungal burden and with greater Th2 (IL-13) immune response. Higher CD4 count was protective despite an increased propensity for immune-mediated damage, consistent with damage-response framework.NCT01075152 and NCT01802385.